Medical condition
Hepatitis B
Hepatitis B is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- entecavir (ENTAC) Antiinfectives for systemic use (J05)
- tenofovir alafenamide (VEMLIDY) Antiinfectives for systemic use (J05)
- lamivudine (3TC) Antiinfectives for systemic use (J05)
- peginterferon alfa-2a (PEGASYS) Antineoplastic and immunomodulating agents (L03)
- adefovir dipivoxil (HEPSERA) Antiinfectives for systemic use (J05)
- telbivudine (SEBIVO) Antiinfectives for systemic use (J05)
- tenofovir disoproxil (TENOFOVIR ARX) Antiinfectives for systemic use (J05)
- human hepatitis b immunoglobulin (ZUTECTRA) Antiinfectives for systemic use (J06)
- hepatitis b surface antigens recombinant (s, pre-s1, pre-s2) adsorbed on aluminium hydroxide [produced on genetically engineered murine (c127i) cells] (HEPACARE) Antiinfectives for systemic use (J07)
- hepatitis b surface antigen (HEPLISAV B) Antiinfectives for systemic use (J07)
- hepatitis b (rdna) vaccine (adjuvanted, adsorbed) (FENDRIX) Antiinfectives for systemic use (J07)
- hepatitis a (inactivated) and hepatitis b (rdna) (hab) vaccine (adsorbed) (AMBIRIX) Antiinfectives for systemic use (J07)
Latest Hepatitis B news
Hepatitis B Drug Developments and Lilly's Obesity Drug Returns
This article discusses the latest advancements in hepatitis B drug development and the implications of CVS reinstating Lilly's obesity drug on formularies.
Latest Developments on Ebola, Hepatitis B, and Long Covid
This article covers the most recent developments in Ebola, hepatitis B, and long Covid, highlighting their implications for the pharmaceutical industry.
GSK and Ionis Present Promising Hepatitis B Drug Data
GSK and Ionis have unveiled significant data on their hepatitis B drug, presenting a potential functional cure. This development could reshape treatment strategies in the pharmaceutical industry.
New Data on Experimental Hepatitis B Treatment: A Functional Cure
Recent findings indicate that an experimental treatment for hepatitis B has achieved a functional cure in nearly one in five patients, signaling potential shifts in the market.